| Released | Contributor | Author | Title | Pages | Price |
| 10-Feb-2010 | Pechala's Reports | Lubomir Pechala | ACURA PHARMACEUTICALS INC (ACUR=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 9-Feb-2010 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 9-Feb-2010 | EconomicInvestor |
N/A
| "The Economy Matters" Report for ACUR: the economy's impact on ACUR's price and risk, featuring the powerful EconomicInvestor Star Rating | 6 |
$15 |
| 8-Feb-2010 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for ACUR | 13 |
$25 |
| 6-Feb-2010 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 6-Feb-2010 | Standard & Poor's Quantitative Report |
N/A
| Acura Pharmaceuticals | 5 |
$25 |
| 5-Feb-2010 | Pechala's Reports | Frantisek Pechala | ACURA PHARMACEUTICALS INC (ACUR=US) 12-months forecast | 1 |
$15 |
| 5-Feb-2010 | Pechala's Reports | Lubomir Pechala | ACURA PHARMACEUTICALS INC (ACUR=US) 2-weeks forecast | 1 |
$10 |
| 4-Feb-2010 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: ACUR , AMLN , LCI , MTXX , SLXP -- DRUGS | 3 |
$4 |
| 4-Feb-2010 | Ford Investor Services, Inc. |
N/A
| Value Graph: ACURA PHARMACEUT -- ACUR | 1 |
$4 |
0.67% Nasdaq 
Research Reports
